查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2011834

數位療法市場：2026-2032年全球市場預測（依產品類型、治療領域、平台、通路類型、最終用戶和部署模式分類）

Digital Therapeutics Market by Product Type, Therapy Area, Platform, Channel Type, End User, Deployment Mode - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024 年數位療法市場價值 56.1 億美元，預計到 2025 年將成長至 64.1 億美元，複合年成長率為 15.72%，到 2032 年將達到 180.5 億美元。

主要市場統計數據
基準年 2024 56.1億美元
預計年份：2025年 64.1億美元
預測年份 2032 180.5億美元
複合年成長率 (%) 15.72%

相關人員主導的趨勢正在重新定義數位療法，並重塑技術、證據和商業模式的臨床實施。

數位療法已成為一類基於實證醫學的醫療介入手段，透過軟體實現疾病的預防、管理或治療。這些干預措施結合了臨床最佳實踐、監管監督和真實世界數據的收集，從而創造治療價值，補充甚至在某些情況下取代傳統的藥物療法和醫療設備療法。該領域的發展趨勢體現在技術的快速創新、某些司法管轄區監管規定的逐步明確，以及越來越多的保險公司和醫療服務提供者尋求可衡量的療效和具有成本效益的治療路徑。

技術、監管政策的澄清以及不斷變化的商業性獎勵如何共同作用，重塑臨床和企業相關人員的採取路徑？

數位療法領域正經歷著一場變革性的轉型，其驅動力來自多方面因素：軟體介入技術的進步、遠距遠端醫療技術的日益普及以及越來越多的臨床療效證據。科技的成熟使得感測器整合更加強大，穿戴式裝置具備更完善的遠端監測功能，從而加強了患者生成數據與臨床決策之間的連結。同時，虛擬實境和身臨其境型體驗正成為復健和心理健康領域差異化的治療方式，為行為改變和治療參與開闢了新的途徑。

評估 2025 年新收費系統對硬體依賴型解決方案、採購經濟和供應鏈策略的廣泛和累積影響。

2025年新關稅的實施將對數位療法生態系統產生複雜的影響，其累積效應將波及供應鏈、設備供應和營運成本。依賴硬體的解決方案，尤其是那些整合穿戴裝置、感測器和專用周邊設備的解決方案，如果零件和成品均需繳納進口關稅，則將面臨更高的投入成本。這些成本壓力可能會蔓延至遠端監測套件和捆綁式疾病管理解決方案，導致價格上漲，迫使開發人員重新思考籌資策略和產品配置。

基於細分的詳細見解，確定每個治療領域、交付模式和實施方法的臨床、技術和商業性重點。

市場區隔洞察揭示了不同的機會領域和風險因素，這些都需要精準的打入市場策略。基於治療領域，臨床重點包括心血管疾病（如心律不整、心臟衰竭和高血壓）；糖尿病亞型（如妊娠糖尿病、1 型糖尿病和第 2 型糖尿病）；精神健康領域（如焦慮症、憂鬱症、創傷後壓力乳癌(PTSD) 和壓力管理）；神經系統疾病（如氣喘、慢性阻塞性肺病每個治療領域都有其獨特的證據標準、患者依從性模式和臨床醫生工作流程，這些都會影響產品設計和監管路徑。

將各地區的市場動態進行比較，並透過針對美洲、歐洲、中東和非洲以及亞太市場的個人化方法，提供商業化的實用見解。

區域趨勢導致監管、報銷和部署環境存在差異，進而影響策略重點。在美洲，市場促進因素包括支付方的參與、雇主主導的健康計畫以及重視行動和雲端干預措施的、具備技術素養的患者群體。雖然某些司法管轄區的監管清晰性為臨床有效性檢驗和報銷提供了明確的途徑，但州和支付方層面的政策差異使得必須制定針對當地決策者的、具有針對性的證據。

透過跨通路臨床檢驗、互通性和適應性經營模式，制定競爭和夥伴關係策略，使領導者脫穎而出。

主要企業之間的競爭格局由一系列策略塑造而成，這些策略強調臨床檢驗、平台擴充性以及與整個醫療生態系統建立策略夥伴關係。市場領導優先進行隨機對照試驗和產生真實世界數據 (RWE)，以滿足支付方和醫療服務提供者的期望，同時投資於互通性和應用程式介面 (API)，以實現與電子健康記錄 (EHR) 和遠端監測系統的整合。與醫療設備製造商、感測器供應商和專科診所的夥伴關係，能夠加快疾病特異性解決方案的上市速度，並支援提供全面的醫療服務。

在不斷變化的市場環境中，開發人員和企業相關人員在加速採用和保護利潤率方面面臨的實際策略挑戰和優先事項。

產業領導者應制定一系列切實可行的優先事項，協調產品開發、證據產生和商業性執行。首先，投資穩健的臨床項目，包括隨機對照試驗和可操作的真實世界研究，這些研究應針對特定的治療領域，例如心血管疾病亞型、糖尿病患者群體、神經系統疾病、輔助性治療和呼吸系統疾病。其次，建構可跨雲端和本地部署的模組化解決方案，以滿足企業對資料主權和延遲敏感型工作流程的多樣化需求。

採用透明的混合方法研究途徑，將第二手資料與關鍵相關人員的檢驗結合，可以產生可操作和可複製的策略見解。

本研究採用混合方法，整合了全面的二手資料研究和與關鍵相關人員的直接溝通，以驗證研究結果並闡明行業趨勢。二手資料分析整合了監管檢驗、同行評審的臨床文獻、技術能力報告以及公開發布的合作關係和產品公告，以揭示不斷演變的行業趨勢。一手資料研究包括對臨床醫生、保險公司、企業健康管理專案經理、技術架構師和企業高管進行結構化訪談，以確定推動技術應用、採購挑戰以及對證據的期望。

綜合結論強調臨床有效性、互通性和商業性靈活性是數位療法永續發展的重要支柱。

數位療法如今已成為臨床護理和軟體創新之間的策略性交匯點，為不斷擴展的治療領域和交付模式提供可擴展的、循證的干涉措施。該領域的短期發展趨勢將取決於企業能否證明其臨床療效，能否使商業模式與買家預期相符，以及能否適應影響硬體依賴型解決方案的宏觀經濟因素，例如關稅。與臨床工作流程的整合、互通性以及對真實世界數據的關注，對於將試點部署發展成為獲得資助的大規模計畫至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 數位療法市場：依產品類型分類

  • 無需處方箋/非處方（OTC）數位藥物
  • 處方箋數位藥物（PDTx）

第9章：按治療領域分類的數位療法市場

  • 糖尿病管理
  • 神經系統疾病
    • 憂鬱症
    • 焦慮症
    • 思覺失調症
    • 癲癇
    • 多發性硬化症
  • 肥胖和體重管理
  • 慢性呼吸系統疾病
  • 心血管疾病
  • 心理和行為健康
  • 肌肉骨骼疾病/疼痛管理
  • 癌症支持護理
  • 消化系統疾病
  • 禁止抽煙
  • 女性健康
  • 復健和物理治療
  • 物質使用障礙
  • 睡眠障礙

第10章 數位療法市場：依平台分類

  • 智慧型手機應用程式
  • 穿戴式裝置整合 DTx
  • 基於人工智慧/機器學習的數位療法
  • 基於虛擬實境（VR）的數位化治療
  • 數位監控+回饋系統
  • 網路/跨平台的治療

第11章 按通路類型分類的數位療法市場

  • 病人/直接面對消費者 (D2C)
  • 醫療服務提供者（醫院和診所）
  • 雇主/公司的健康計劃
  • 與製藥公司合作
  • 政府和公共衛生系統

第12章 數字療法市場：依最終用戶分類

  • 病人
  • 醫護人員
  • 雇主和企業健康
  • 看護者及復健中心

第13章 數位療法市場：依部署模式分類

  • 基於雲端的
  • 現場
  • 混合實現

第14章 數位療法市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 數位療法市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 數位療法市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國數位療法市場

第18章：中國數字療法市場

第19章 競爭情勢

  • 2024年市場集中度分析
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2024 年
  • 2024年產品系列分析
  • 基準分析，2024 年
  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd
  • Noom, Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Omada Health, Inc.
  • Otsuka Holdings Co., Ltd.
  • ResMed, Inc.
  • Teladoc Health, Inc.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-431752EA4722

The Digital Therapeutics Market was valued at USD 5.61 billion in 2024 and is projected to grow to USD 6.41 billion in 2025, with a CAGR of 15.72%, reaching USD 18.05 billion by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.61 billion
Estimated Year [2025] USD 6.41 billion
Forecast Year [2032] USD 18.05 billion
CAGR (%) 15.72%

Defining digital therapeutics and the stakeholder-driven dynamics reshaping clinical adoption across technology, evidence, and commercial models

Digital therapeutics have emerged as an evidence-driven category of medical interventions delivered through software to prevent, manage, or treat medical conditions. These interventions bridge clinical best practices, regulatory oversight, and real-world data capture to create therapeutic value that complements or, in some instances, substitutes traditional pharmacologic and device-based care. The landscape is defined by rapid technological innovation, increased regulatory clarity in some jurisdictions, and rising adoption among payers and providers seeking measurable outcomes and cost-effective care pathways.

Stakeholders across the ecosystem bring distinct priorities to adoption. Developers emphasize clinical validation, interoperability, and scalable architectures that support cloud and on-premise deployment models. Healthcare providers focus on integration into care pathways and workflow compatibility with clinician roles such as physicians, nurses, and therapists. Employers and payers increasingly evaluate digital therapeutics for chronic condition management and wellness programs, while patients seek user-friendly mobile and web experiences that respect privacy and demonstrate clinical benefit. Delivery modes span cloud, desktop, mobile, virtual reality, and web platforms, and application areas include disease management, rehabilitation, remote monitoring with sensor integration and wearable devices, as well as wellness management.

Consequently, decision makers must balance clinical evidence generation with product usability, regulatory compliance, and commercial models such as licensing, pay-per-use, and subscription structures that can be offered on annual or monthly terms. As adoption accelerates, convergence between health data ecosystems and consumer technologies creates new opportunities and challenges for scalability, reimbursement, and sustained engagement.

How technology, regulatory clarity, and shifting commercial incentives are converging to reshape adoption pathways across clinical and enterprise stakeholders

The digital therapeutics landscape is undergoing transformative shifts driven by converging forces: advances in software-based interventions, greater acceptance of telehealth modalities, and an expanding evidence base demonstrating clinical efficacy. Technology maturation has enabled more robust sensor integration and wearable devices that enhance remote monitoring capabilities, thereby strengthening the bridge between patient-generated data and clinician decision-making. Simultaneously, virtual reality and immersive experiences are emerging as differentiated delivery options for rehabilitation and mental health applications, creating new pathways for behavioral change and therapeutic engagement.

Regulatory evolution and payer receptivity are redefining market access. Clearer pathways for clinical validation and reimbursement are enabling higher-value procurement by healthcare providers, employers, and payers, but they also raise the bar for proof of outcomes and long-term adherence. Pricing models are shifting from one-time licensing to more outcome-oriented subscription structures and pay-per-use arrangements that align incentives between developers and purchasers. Meanwhile, integration imperatives drive enterprise architectures toward hybrid deployment models, balancing cloud scalability with on-premise requirements for data sovereignty and latency-sensitive workloads.

Finally, therapeutic focus is broadening beyond mental health and diabetes into neurology, oncology adjuncts, respiratory disease management, and cardiovascular subsegments such as arrhythmia and heart failure. This diversification increases the importance of tailored clinical pathways, interoperability with electronic health records, and partnerships between digital-native firms and traditional healthcare organizations to accelerate adoption and deliver measurable patient benefit.

Assessing the wide-ranging cumulative effects of new 2025 tariffs on hardware-dependent solutions, procurement economics, and supply chain strategies

The introduction of new tariffs in 2025 presents complex implications for the digital therapeutics ecosystem, with cumulative effects that extend across supply chains, device availability, and operating costs. Hardware-dependent solutions, particularly those incorporating wearable devices, sensors, and specialized peripherals, face increased input costs when components or finished devices are subject to import duties. These cost pressures can cascade into higher prices for remote monitoring kits and bundled disease management solutions, creating a need for developers to reassess sourcing strategies and product configurations.

Service delivery is also affected indirectly. Increased costs for physical devices may change adoption decisions among employers, payers, and patients, incentivizing greater reliance on software-only modalities such as mobile apps and cloud-delivered interventions. At the same time, tariffs can influence the competitive dynamics between domestic manufacturers and international suppliers, prompting greater investment in local manufacturing or alternative component procurement to maintain margins. Cloud-based services might be insulated from hardware levies but could face secondary impacts through changes in enterprise procurement and total cost of ownership calculations.

Regulatory and contractual frameworks will increasingly reflect these economic shifts. Providers and purchasers may renegotiate service agreements, extend device lifecycles through firmware updates and software enhancements, or prioritize interoperable solutions that reduce dependency on proprietary hardware. In the near term, stakeholders should model scenario analyses to understand how tariff-induced cost changes influence pricing strategies, reimbursement negotiations, and product roadmaps, while exploring mitigation through design simplification, regional supply diversification, and closer alignment with clinical stakeholders who value outcome-based payment structures.

Deep segmentation-driven insights identifying differentiated clinical, technological, and commercial priorities across therapeutic areas delivery modes and deployment choices

Segmentation insights reveal differentiated opportunity zones and risk vectors that demand precise go-to-market strategies. Based on therapeutic area, clinical focus ranges across cardiovascular conditions including arrhythmia, heart failure, and hypertension; diabetes subtypes such as gestational, type 1, and type 2; mental health areas encompassing anxiety disorders, depression, posttraumatic stress disorder, and stress management; neurology indications including epilepsy, multiple sclerosis, and Parkinson's disease; oncology subsegments like breast cancer, leukemia, and lung cancer; and respiratory conditions such as asthma and chronic obstructive pulmonary disease. Each therapeutic area exhibits unique evidence thresholds, patient adherence patterns, and clinician workflows that influence product design and regulatory pathways.

Delivery mode segmentation differentiates solutions by platform characteristics including cloud, desktop, mobile, virtual reality, and web. Cloud and mobile formats excel in scalability and patient engagement, whereas desktop and on-premise arrangements can be preferable for enterprise integration and data control. Virtual reality presents distinct value in rehabilitation and mental health modalities where immersive engagement drives therapeutic response. End user segmentation underscores adoption drivers across employers, healthcare providers, patients, and payers, with healthcare providers further divided into nurses, physicians, and therapists who each bring different clinical priorities and usability constraints. Application-based segmentation covers disease management, rehabilitation, remote monitoring with sensor integration and wearable devices, and wellness management, highlighting that remote monitoring requires strong interoperability and secure data pipelines for clinical decision support.

Distribution channels vary between direct approaches, hospital channels, and pharmacy channels, with direct routes further segmented into app stores and company websites that favor rapid consumer access. Pricing model segmentation spans licensing, pay-per-use, and subscription options, where subscription variants can be annual or monthly and influence lifetime value calculations and retention strategies. Deployment models bifurcate into cloud and on-premise, shaping integration complexity, data governance, and total cost of ownership. When combined, these segmentation vectors form a matrix that informs product positioning, clinical evidence generation, and commercial tactics tailored to each stakeholder cohort.

Comparative regional dynamics and practical implications for commercialization with tailored approaches for the Americas, EMEA, and Asia-Pacific markets

Regional dynamics create differentiated regulatory, reimbursement, and adoption environments that influence strategic priorities. In the Americas, market drivers emphasize payer engagement, employer-sponsored health programs, and a technology-literate patient population that values mobile and cloud-delivered interventions. Regulatory clarity in some jurisdictions supports defined pathways for clinical validation and reimbursement, but regional heterogeneity in state- and payer-level policies necessitates focused evidence generation aligned with local decision-makers.

Europe, Middle East & Africa features a mosaic of reimbursement landscapes and regulatory regimes where centralized and national-level health authorities play significant roles. Success in this region often requires interoperability with diverse electronic health record systems, multilingual user experiences, and nuanced pricing strategies to reflect public healthcare procurement processes. Moreover, regional privacy frameworks and data residency concerns can favor on-premise or hybrid deployment models, particularly for enterprise-grade solutions.

Asia-Pacific presents accelerated adoption potential driven by digital-first populations and large-scale public health initiatives, coupled with growing investment in local manufacturing that can mitigate tariff effects. However, fragmented regulatory frameworks and variable payer models require adaptable commercialization approaches and strong local partnerships. Across all regions, partnerships with healthcare providers, payers, and distribution channels remain essential to translate clinical evidence into funded adoption and sustained utilization.

Competitive strategies and partnership plays that differentiate leaders through clinical validation, interoperability, and adaptive commercial models across channels

Competitive behavior among leading companies is shaped by strategies that emphasize clinical validation, platform extensibility, and strategic partnerships across healthcare ecosystems. Market leaders prioritize randomized controlled trials and real-world evidence generation to meet payer and provider expectations, while also investing in interoperability and APIs that enable integration with electronic health records and remote monitoring systems. Partnerships with device manufacturers, sensor suppliers, and specialty clinics accelerate route-to-market for condition-specific solutions and support bundled care offerings.

Mergers, alliances, and licensing agreements are common approaches to address capability gaps in areas such as virtual reality content, advanced analytics, and on-the-ground clinical distribution. Companies focused on subscription and outcome-based pricing are collaborating more closely with payers and employers to create value-based contracts tied to clinical endpoints and utilization metrics. Meanwhile, firms that maintain flexible deployment options-cloud, on-premise, and hybrid-tend to capture enterprise accounts that prioritize data governance and system interoperability.

Smaller innovators often concentrate on niche therapeutic areas and differentiated delivery modes, leveraging direct distribution through app stores and targeted partnerships to achieve scale. Across the competitive landscape, successful companies combine strong clinical evidence, user-centered design, and commercial models that reflect the procurement preferences of employers, healthcare providers, and payers, while maintaining agility to adapt to tariff and regulatory shifts.

Practical strategic imperatives and prioritized actions for developers and enterprise stakeholders to accelerate adoption and protect margins amid evolving market conditions

Industry leaders should pursue a set of actionable priorities that align product development, evidence generation, and commercial execution. First, invest in robust clinical programs that include randomized trials and pragmatic real-world studies tailored to specific therapeutic segments such as cardiovascular subtypes, diabetes cohorts, neurological indications, oncology adjuncts, and respiratory conditions. Second, architect solutions for modular deployment across cloud and on-premise models to meet diverse enterprise requirements for data sovereignty and latency-sensitive workflows.

Third, prioritize platform interoperability and sensor-agnostic remote monitoring to reduce dependency on proprietary hardware and to mitigate exposure to tariff-induced cost fluctuations. Fourth, adopt flexible commercial strategies including subscription tiers and outcome-based contracts that reflect purchaser risk preferences and support long-term engagement. Fifth, cultivate strategic partnerships with device manufacturers, healthcare providers, employers, and payers to enable bundled care propositions and smoother pathways to reimbursement.

Finally, develop region-specific go-to-market plans for the Americas, Europe, Middle East & Africa, and Asia-Pacific that account for regulatory nuance, procurement practices, and patient engagement behaviors. Executing these priorities will require cross-functional coordination between clinical teams, product management, regulatory affairs, and commercial leaders to translate evidence into adoption and sustainable revenue streams.

Transparent mixed-methods research approach combining secondary synthesis and primary stakeholder validation to produce actionable and reproducible strategic insights

This research is grounded in a mixed-methods approach that integrates comprehensive secondary research with primary stakeholder engagements to validate findings and contextualize trends. Secondary analysis synthesized regulatory guidance, peer-reviewed clinical literature, technology capability reports, and publicly disclosed partnership and product announcements to map the evolving landscape. Primary research included structured interviews with clinicians, payers, employer health program managers, technology architects, and company executives to surface adoption drivers, procurement pain points, and evidence expectations.

Segmentation frameworks were developed by mapping therapeutic areas, delivery modes, end users, applications, distribution channels, pricing models, and deployment preferences to observed market behaviors. Where possible, cross-validation techniques were applied to reconcile discrepancies between primary insights and secondary sources, and scenario analysis was used to assess the potential impacts of macroeconomic variables such as tariff changes and supply chain disruptions. Limitations of the methodology include evolving regulatory actions and proprietary commercial agreements that may not yet be publicly visible, and therefore findings emphasize directional insights and actionable strategies rather than definitive commercial forecasts.

Transparency in assumptions and a clear audit trail of sources were maintained throughout the research process to support reproducibility and client-specific tailoring of the final deliverables.

Consolidated conclusion emphasizing clinical validation interoperability and commercial agility as the essential pillars for sustainable growth in digital therapeutics

Digital therapeutics now occupy a strategic intersection of clinical care and software innovation, offering scalable, evidence-based interventions across a widening set of therapeutic areas and delivery modes. The sector's near-term trajectory will be shaped by the ability of companies to demonstrate clinical outcomes, align commercial models with purchaser expectations, and adapt to macroeconomic influences such as tariffs that affect hardware-dependent solutions. Integration with clinical workflows, interoperability, and a focus on real-world evidence are central to converting pilot implementations into funded, large-scale programs.

Moreover, regional differences in regulation, reimbursement, and adoption behavior require tailored go-to-market approaches that respect local procurement norms while leveraging platform-level efficiencies. Competitive advantage will accrue to organizations that combine rigorous clinical validation with flexible deployment strategies, strategic partnerships, and pricing models that share risk and reward with payers and providers. In sum, success in digital therapeutics depends on an orchestration of clinical credibility, technical interoperability, and commercial ingenuity that together enable measurable patient impact and sustainable business models.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2024
  • 3.5. FPNV Positioning Matrix, 2024
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Digital Therapeutics Market, by Product Type

  • 8.1. Non-Prescription / Over-the-Counter (OTC) Digital Therapeutics
  • 8.2. Prescription Digital Therapeutics (PDTx)

9. Digital Therapeutics Market, by Therapy Area

  • 9.1. Diabetes Management
  • 9.2. Neurological Disorders
    • 9.2.1. Depression
    • 9.2.2. Anxiety Disorders
    • 9.2.3. Schizophrenia
    • 9.2.4. Epilepsy
    • 9.2.5. Multiple Sclerosis
  • 9.3. Obesity & Weight Management
  • 9.4. Chronic Respiratory Diseases
  • 9.5. Cardiovascular Diseases
  • 9.6. Mental & Behavioral Health
  • 9.7. Musculoskeletal Disorders / Pain Management
  • 9.8. Oncology Support Care
  • 9.9. Gastrointestinal Disorders
  • 9.10. Smoking Cessation
  • 9.11. Women's Health
  • 9.12. Rehabilitation & Physical Therapy
  • 9.13. Substance Use Disorders
  • 9.14. Sleep Disorders

10. Digital Therapeutics Market, by Platform

  • 10.1. Smartphone-Based Applications
  • 10.2. Wearable Device-Integrated DTx
  • 10.3. AI/ML-Based Digital Therapies
  • 10.4. Virtual Reality (VR)-Based DTx
  • 10.5. Digital Monitoring + Feedback Systems
  • 10.6. Web-Based / Cross-Platform Therapeutics

11. Digital Therapeutics Market, by Channel Type

  • 11.1. Patients / Direct-to-Consumer (D2C)
  • 11.2. Healthcare Providers (Hospitals & Clinics)
  • 11.3. Employers / Corporate Wellness Programs
  • 11.4. Pharmaceutical Partnerships
  • 11.5. Government & Public Health Systems

12. Digital Therapeutics Market, by End User

  • 12.1. Patients
  • 12.2. Healthcare Providers
  • 12.3. Employers & Corporate Wellness
  • 12.4. Caregivers & Rehabilitation Centers

13. Digital Therapeutics Market, by Deployment Mode

  • 13.1. Cloud-Based
  • 13.2. On-Premise
  • 13.3. Hybrid Deployment

14. Digital Therapeutics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Digital Therapeutics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Digital Therapeutics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Digital Therapeutics Market

18. China Digital Therapeutics Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2024
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2024
  • 19.3. Product Portfolio Analysis, 2024
  • 19.4. Benchmarking Analysis, 2024
  • 19.5. Abbott Laboratories
  • 19.6. F. Hoffmann-La Roche Ltd
  • 19.7. Noom, Inc.
  • 19.8. Novartis AG
  • 19.9. Novo Nordisk A/S
  • 19.10. Omada Health, Inc.
  • 19.11. Otsuka Holdings Co., Ltd.
  • 19.12. ResMed, Inc.
  • 19.13. Teladoc Health, Inc.
  • 19.14. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DIGITAL THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 3. GLOBAL DIGITAL THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 4. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES DIGITAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA DIGITAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY NON-PRESCRIPTION / OVER-THE-COUNTER (OTC) DIGITAL THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY NON-PRESCRIPTION / OVER-THE-COUNTER (OTC) DIGITAL THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY NON-PRESCRIPTION / OVER-THE-COUNTER (OTC) DIGITAL THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DIGITAL THERAPEUTICS (PDTX), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DIGITAL THERAPEUTICS (PDTX), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DIGITAL THERAPEUTICS (PDTX), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY DIABETES MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY DIABETES MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY DIABETES MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY DEPRESSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY DEPRESSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY DEPRESSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY ANXIETY DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY ANXIETY DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY ANXIETY DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY SCHIZOPHRENIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY SCHIZOPHRENIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY SCHIZOPHRENIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY EPILEPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY OBESITY & WEIGHT MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY OBESITY & WEIGHT MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY OBESITY & WEIGHT MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY CHRONIC RESPIRATORY DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY CHRONIC RESPIRATORY DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY CHRONIC RESPIRATORY DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY MENTAL & BEHAVIORAL HEALTH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY MENTAL & BEHAVIORAL HEALTH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY MENTAL & BEHAVIORAL HEALTH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY MUSCULOSKELETAL DISORDERS / PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY MUSCULOSKELETAL DISORDERS / PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY MUSCULOSKELETAL DISORDERS / PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY ONCOLOGY SUPPORT CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY ONCOLOGY SUPPORT CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY ONCOLOGY SUPPORT CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY SMOKING CESSATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY SMOKING CESSATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY SMOKING CESSATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY WOMEN'S HEALTH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY WOMEN'S HEALTH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY WOMEN'S HEALTH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY REHABILITATION & PHYSICAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY REHABILITATION & PHYSICAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY REHABILITATION & PHYSICAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY SUBSTANCE USE DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY SUBSTANCE USE DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY SUBSTANCE USE DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY SLEEP DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY SLEEP DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY SLEEP DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY SMARTPHONE-BASED APPLICATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY SMARTPHONE-BASED APPLICATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY SMARTPHONE-BASED APPLICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY WEARABLE DEVICE-INTEGRATED DTX, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY WEARABLE DEVICE-INTEGRATED DTX, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY WEARABLE DEVICE-INTEGRATED DTX, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY AI/ML-BASED DIGITAL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY AI/ML-BASED DIGITAL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY AI/ML-BASED DIGITAL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY VIRTUAL REALITY (VR)-BASED DTX, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY VIRTUAL REALITY (VR)-BASED DTX, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY VIRTUAL REALITY (VR)-BASED DTX, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY DIGITAL MONITORING + FEEDBACK SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY DIGITAL MONITORING + FEEDBACK SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY DIGITAL MONITORING + FEEDBACK SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY WEB-BASED / CROSS-PLATFORM THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY WEB-BASED / CROSS-PLATFORM THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY WEB-BASED / CROSS-PLATFORM THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY PATIENTS / DIRECT-TO-CONSUMER (D2C), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY PATIENTS / DIRECT-TO-CONSUMER (D2C), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY PATIENTS / DIRECT-TO-CONSUMER (D2C), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY HEALTHCARE PROVIDERS (HOSPITALS & CLINICS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY HEALTHCARE PROVIDERS (HOSPITALS & CLINICS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY HEALTHCARE PROVIDERS (HOSPITALS & CLINICS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY EMPLOYERS / CORPORATE WELLNESS PROGRAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY EMPLOYERS / CORPORATE WELLNESS PROGRAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY EMPLOYERS / CORPORATE WELLNESS PROGRAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL PARTNERSHIPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL PARTNERSHIPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL PARTNERSHIPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY GOVERNMENT & PUBLIC HEALTH SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY GOVERNMENT & PUBLIC HEALTH SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY GOVERNMENT & PUBLIC HEALTH SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY HEALTHCARE PROVIDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY HEALTHCARE PROVIDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY HEALTHCARE PROVIDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY EMPLOYERS & CORPORATE WELLNESS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY EMPLOYERS & CORPORATE WELLNESS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY EMPLOYERS & CORPORATE WELLNESS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY CAREGIVERS & REHABILITATION CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY CAREGIVERS & REHABILITATION CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY CAREGIVERS & REHABILITATION CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY CLOUD-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY CLOUD-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY CLOUD-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY ON-PREMISE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY ON-PREMISE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY ON-PREMISE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY HYBRID DEPLOYMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY HYBRID DEPLOYMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY HYBRID DEPLOYMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS DIGITAL THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA DIGITAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA DIGITAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA DIGITAL THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE DIGITAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST DIGITAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA DIGITAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN DIGITAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 200. GCC DIGITAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. GCC DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. GCC DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 203. GCC DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 204. GCC DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 205. GCC DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. GCC DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. GCC DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION DIGITAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS DIGITAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 224. G7 DIGITAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. G7 DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. G7 DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 227. G7 DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 228. G7 DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 229. G7 DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. G7 DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. G7 DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 232. NATO DIGITAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 233. NATO DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. NATO DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 235. NATO DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 236. NATO DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 237. NATO DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. NATO DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. NATO DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 240. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES DIGITAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA DIGITAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)